DsiRNA Androgen Receptor Inhibition via Dicer Processing

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for prostate cancer, particularly in castration-resistant cases, face challenges due to increased androgen receptor expression and local androgen production, leading to resistance against standard therapies, necessitating more effective AR inhibition methods.

Innovation Solution

Development of Dicer substrate siRNAs (DsiRNAs) with specific structures and modifications that are potent AR inhibitory agents, capable of reducing AR gene expression by targeting the androgen receptor cDNA sequences, offering enhanced potency and duration of inhibitory effect compared to traditional 21 nucleotide siRNAs.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If traditional 21 nucleotide siRNAs are used to inhibit androgen receptor, then AR gene expression is reduced, but the inhibitory effect has limited potency and short duration due to resistance mechanisms

Engineering Contradiction:

Improveinhibitory effectVSAvoidduration of inhibition

Core Design Contradiction:

ReliabilityVSDuration of action of moving object

Solution Approach 1:

The patent modifies the siRNA structure by extending the length from 21 nucleotides to 27-35 nucleotides and adding specific overhangs (1-5 nucleotides at 3' ends), which changes the physical parameters of the molecule to enhance Dicer processing efficiency and produce more effective RNAi products with longer duration of action

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates composite siRNA structures combining double-stranded RNA with specific single-stranded overhangs, forming a hybrid structure that is optimally processed by Dicer enzyme to generate potent RNAi effects with extended durability against resistant cancer cells

Inventive Principle:

Principle #40Composite materials

2Productivity

If standard therapies are used to treat prostate cancer, then initial treatment response is achieved, but resistance develops due to increased androgen receptor expression and local androgen production

Engineering Contradiction:

Improvetreatment efficacyVSAvoidresistance to therapy

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent employs siRNAs with extended sequences that are pre-designed to be more effectively processed by Dicer into potent RNAi products, creating a more robust and sustained inhibition of androgen receptor expression before resistance can develop, thereby preventing treatment failure

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The modified siRNA structures provide continuous and sustained suppression of androgen receptor gene expression through enhanced Dicer processing and more stable RNAi activity, maintaining therapeutic efficacy over extended periods without interruption by resistance mechanisms

Inventive Principle:

Principle #20Continuity of useful action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The DsiRNAs effectively reduce AR target gene expression by up to 99% at low concentrations, demonstrating greater potency and longer-lasting inhibition than conventional siRNAs, potentially addressing treatment resistance in prostate cancer.

Implementation Method 1

dsRNA agents of such length are believed to be processed by the Dicer enzyme of the RNA interference (RNAi) pathway

Methodology Applied

Scientific EffectRNA interference:

Data Source

PatentUS8927515B2Methods and compositions for the specific inhibition of androgen receptor by double-stranded RNA

Publication Date: 2015.01.06 DICERNA PHARMACEUTICALS INC

AI summary

This invention relates to compounds, compositions, and methods useful for reducing AR target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.